Target Information

Target General Information

Top

Target ID

T57585 (Former ID: TTDI01571)

Target Name

Chloride channel unspecific (ClC)

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 3 Target-related Diseases

Chronic obstructive pulmonary disease [ICD-11: CA22]

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Brain cancer [ICD-11: 2A00]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Clinical Trial Drug(s)

[+] 4 Clinical Trial Drugs

131I-TM-601

Drug Info

Phase 2

Glioma

[2]

Lancovutide

Drug Info

Phase 2

Chronic obstructive pulmonary disease

[3], [4]

TM-601

Drug Info

Phase 2

Solid tumour/cancer

[5]

BLZ-100

Drug Info

Phase 1/2

Glioma

[6]

Discontinued Drug(s)

[+] 2 Discontinued Drugs

GR-213487

Drug Info

Discontinued in Phase 2

Cystic fibrosis

[7]

TgAAV-CFTR

Drug Info

Discontinued in Phase 2

Cystic fibrosis

[8]

Mode of Action

[+] 2 Modes of Action

Inhibitor

[+] 3 Inhibitor drugs

131I-TM-601

Drug Info

[11]

TM-601

Drug Info

[5]

BLZ-100

Drug Info

[6]

Modulator

[+] 3 Modulator drugs

Lancovutide

Drug Info

[12]

GR-213487

Drug Info

[13]

TgAAV-CFTR

Drug Info

[14]

References

Top

REF 1

Haemonchus contortus: selection at a glutamate-gated chloride channel gene in ivermectin- and moxidectin-selected strains. Exp Parasitol. 1998 Sep;90(1):42-8.

REF 2

ClinicalTrials.gov (NCT00114309) 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma. U.S. National Institutes of Health.

REF 3

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 841).

REF 4

ClinicalTrials.gov (NCT00671736) Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis. U.S. National Institutes of Health.

REF 5

NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21.

REF 6

Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.

REF 7

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010993)

REF 8

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011201)

REF 9

REF 10

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013896)

REF 11

Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6.

REF 12

Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59.

REF 13

EP patent application no. 1336602, Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases.

REF 14

Novel molecular approaches to cystic fibrosis gene therapy. Biochem J. 2005 April 1; 387(Pt 1): 1-15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU